Drugs / HER-2/neu peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01632332 | Jul 2012 → Mar 2014 | HER2 positive breast carcinoma, male breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER-2/neu peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01632332 ↗ |
| Modality | Vaccine | “a peptide-based vaccine targeting HER-2/neu” NCT01632332 ↗ |